People | February 20, 2022
Resolution Therapeutics strengthens its team with two new appointments
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
This approval authorizes the company to export Ibuprofen to the Chinese markets
Subscribe To Our Newsletter & Stay Updated
